The existing expertise ranges from conditions where Tau plays neuropathological roles (FTD and certain APD) to newly recognized neurodegenerative diseases (i.e., MS) where the Tau protein represents an interesting axonal damage biomarker that will be further investigated in the future. Here, MAPT is linked to frontotemporal dementia.